This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Developed by Zuellig Pharma, eZRx is ASEAN’s largest B2B eCommerce platform for the healthcare industry – offering a smarter and more convenient way to buy and sell healthcare products online, anywhere and anytime, versus reps visiting clients face-to-face. And it happened to launch when the world needed it most.
WALK FASTER: Develop cloud adoption planning and migration roadmap With the CoE and EA teams working in tandem, its time to engage the business stakeholders/product owners and develop the plan and roadmap. The effectiveness of the cloud CoE comes into play in this phase.
The pharmaceutical industry is a highly regulated one, especially for multinationals doing business across the globe. Merck Life Sciences, a leading chemical and pharmaceutical company, with 60,000 employees working across 66 countries, was one of them. In the development control room, there are 25 users with different roles.
Eli Lilly overcomes translation bottleneck: With global teams working in a variety of languages, the pharmaceutical firm developed Lilly Translate, a home-grown NLP solution, to help translate everything from internal training materials and formal, technical communications to regulatory agencies. NLTK is offered under the Apache 2.0
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax Photo). Net losses were $5.3 million in 2019 and $18.9
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Simpson was formerly the CEO of PvP Biologics, another IPD spinout, which he oversaw from the company’s launch through its sale to the pharmaceutical company Takeda. Icosavax Photo).
The startup has an exclusive license to use novel CAR T-cell technology developed by Jensen and his team. BrainChild Bio will take with it about 18 people research and development employees from Seattle Children’s Therapeutics, which will continue working on childhood leukemia, lupus and other diseases.
New Athira execs Mark Worthington, general counsel, and Rachel Lenington, chief technology officer and head of product development strategy. Athira Pharma recently appointed Rachel Lenington as CTO and head of product development strategy and Mark Worthington as general counsel. Athira Photos). The Bothell, Wash.-based Read the story.
The nonprofit Mars Society is getting set to take the next giant leap in its mission to support Red Planet exploration and settlement, by establishing a Mars Technology Institute to develop the tools and processes those settlers will need. A computer-generated image shows an early Mars settlement.
CaaMTech , a Seattle-area startup developing new psychedelic agents, has raised $22 million in funding, the company announced this week. CaaMTech is developing a suite of tryptamines with the aim of finding mixes that “optimize desired effects while minimizing unwanted side-effects,” according to the company’s website.
The funding will fuel Alpine’s program developing ALPN-303, designed to treat lupus and other inflammatory diseases. That payment is part of a licensing deal inked last year with the pharmaceutical giant for clinical testing of another immune-modulating agent, ALPN-101, for lupus.
Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug. million Americans.
This is a major shift for the country that is the European headquarters for many large US pharmaceutical companies, as well as tech firms, including Google, Apple, and Facebook. Companies typically create Irish subsidiaries of their companies that license their intellectual property, on which the subsidiary pays royalties.
AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. The UW has licensed the exclusive rights of this intellectual property to the startup. Another Seattle-area biotech startup, Athira Pharma, is also developing treatments for Alzheimer’s.
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. billion if development milestones are met, and another $1.75
The company plans to apply those technologies in the development of software-as-a-service products for the enterprise, tackling problems such as cybersecurity, navigation, and drug discovery. Or of formulas and know-how and trade secrets at pharmaceutical and biotech companies. Hidary, an energetic figure, is a serial entrepreneur.
On March 21, CEO Jensen Huang (pictured) told attendees at the company’s online-only developer conference, GTC 2023, about a string of new services Nvidia hopes enterprises will use to train and run their own generative AI models. As the generative AI bandwagon gathers pace , Nvidia is promising tools to accelerate it still further.
Double strands of innovation: TwinStrand, which spun out of the University of Washington, has developed technology in both gene sequencing and analyzing sequencing results to help it find what the company calls “genetic needles in the haystack.” Total venture capital funding is now north of $70 million for the 6-year-old company.
Founded in 2018, Vouched helps companies verify the identity of customers and users by examining driver’s licenses and other forms of identification. AGC Biologics is a “Contract Development and Manufacturing Organization” that helps companies develop and produce pharmaceuticals and other medical treatments.
“When I founded the company, I never really expected to get a product on the market to patients,” said Hoekman, who served as CEO until 2017 and is now chief technology and development officer. It’s been a “big challenge to shift from a device technology-focused company to what is now a pretty integrated pharmaceutical company,” said Hoekman.
“David said, ‘Well, George, if we do this, no one’s going to develop it for you. They licensed the AbC technology from UW and incorporated Archon Biosciences in 2023. … Have you ever thought about starting a company?'” ” Ueda recalled. “I said, ‘No, but I can’t not do this.’
GeekWire Photo / Charlotte Schubert) The Institute for Protein Design at the University of Washington is a startup factory , spinning out companies developing new protein-based therapeutics, industrial enzymes, materials, biosensors and more. billion acquisition of IPD spinout Icosavax, which develops vaccines.
The investment firm’s team includes senior associate Dasom (Christine) Yoo , former Fred Hutchinson Cancer Research Center business development manager. However, the company said the papers containing altered images were not cited in its patent filing for its lead development candidate, ATH-1017. GeekWire Photo / Kevin Lisota).
To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. Varda has been working on a space-based manufacturing system that processes materials in orbit to produce pharmaceuticals, with the finished products shipped back down to Earth.
Open innovation , the most talked-about development in corporate innovation, is fundamentally based on tapping external networks. Examples included Cisco’s extended network, value flows in the pharmaceutical industry and an engineering firm, among others. Free chapters) Implementing Enterprise 2.0
It took less than six hours for drug-developing AI to invent 40,000 potentially lethal molecules. The AI came up with tens of thousands of new substances, some of which are similar to VX, the most potent nerve agent ever developed. He’s also a senior scientist at Collaborations Pharmaceuticals, Inc.,
Each of these companies has developed fairly mature offerings, and gained traction in the corporate marketplace, with a number of leading audit firms, investment banks, and pharmaceutical companies in the process of implementing their software. See some screenshots here. Free chapters) Implementing Enterprise 2.0
Executive Forum , one of the showcased companies, Janssen-Cilag, an Australian pharmaceutical subsidiary of Johnson & Johnson, gave us a snapshot of an internal tool they’ve developed called Jitter (see Nathan Wallace’s presentation and resources on his blog ), which is essentially Twitter for the enterprise.
So you buy a processing unit design from somebody like Arm in the UK, who is very popular, and then maybe you need the USB interface, so you get a USB IP block, which you license. So you decide, “I want to build a controller chip.” And by the way, DARPA had funded pandemic preparedness research at Moderna half a decade ago.
Neuralink, a startup co-founded by Musk in 2016, aims to develop a brain chip implant that it claims could one day help paralyzed people walk and blind people see. The same goes for inventing important new medical devices, pharmaceutical drugs, and vaccines. It’s what Winders calls “animal experimentation exceptionalism.”.
Intimate relationships now can be developed online via email, text messaging and phone sex, and they can be ended this way, too. Printing gave rise to the production of "penny dreadfuls," while one of the early developments of still photography was the "what the butler saw" machine. At the time this article was written, a U.S.
But even more important is to think about the technologies you are developing for the next long phase, which is about Resilience for the future. And I’ll earn my A-class license on iRacing…. The tech industry has contributed to polarization through the various social media platforms that we developed. The tech backlash is real.
to come out firmly for the TRIPS [intellectual property] waivers so that we could license these vaccines around the globe, wherever there was capacity, and make sure that we could produce them in other countries. . “The U.S. and all of the other wealthier countries have to put a lot more money in.” That is really critical.
Indeed, the US government’s record to date on AI has mostly involved vague calls for “continued United States leadership in artificial intelligence research and development” or “adoption of artificial intelligence technologies in the Federal Government,” which is fine, but not exactly concrete policy. Principles, rather than programming.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content